Phase 1 data for BGE-102 demonstrates significant reductions in hsCRP and inflammatory biomarkers, positioning it as a potential best-in-class therapy for cardiovascular risk and age-related inflammat...
Recent studies reveal MG53 (TRIM72) enhances muscle stem cell activation and reduces inflammation, offering a novel therapeutic target for sarcopenia with promising preclinical and early clinical resu...
